logo
Share SHARE
FONT-SIZE Plus   Neg

Mylan, Pfizer Announce Epinephrine Auto-injector Settlement Agreement With Teva

Mylan Inc. (MYL) said Meridian Medical Technologies, a Pfizer (PFE) subsidiary, has entered into a settlement agreement with Teva (TEVA) that will resolve pending patent litigation related to its abbreviated new drug application for a generic epinephrine auto-injector.

According to the settlement terms, Teva may launch a generic epinephrine auto-injector covered by its ANDA on June 22, 2015 or earlier under certain circumstances, subject to receipt of approval from the U.S. Food and Drug Administration. Teva currently does not have tentative approval from the FDA for its epinephrine auto-injector product.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Database startup MongoDB has filed confidentially for initial public offering, aiming to go public before the end of the year, according to TechCrunch. The company, which develops enterprise-grade, open-source software including MongoDB NoSQL database, reportedly has submitted an S-1 filing in the past few weeks. Wal-Mart Stores Inc., the world's largest retailer, reported a decline in second-quarter profit with a significant charge. Adjusted earnings topped analysts' estimates with higher comparable sales. Looking ahead, for the third quarter, the company projects earnings in line or below market view. The company also issued earnings forecast for fiscal 2018. The development of Alzheimer's drugs has been marred by a high failure rate. A U.S. study, which analyzed how the Alzheimer's clinical trials fared during the period of 2002 to 2012, revealed a failure rate of 99.6% compared to a failure rate of 81% for cancer drugs.
comments powered by Disqus
Follow RTT